Mabwell (Shanghai) Bioscience Co., Ltd. announced that its board approved an application to the National Association of Financial Market Institutional Investors (NAFMII) for the registration and issuance of targeted debt financing instruments with a ceiling of RMB1.00 billion.

The proposed registration will remain effective for two years, while each tranche may carry a tenor of up to three years and will be placed in the interbank bond market with institutional investors. The coupon rate is to be set according to prevailing market conditions.

Proceeds are earmarked for repaying interest-bearing liabilities, funding project construction and replenishing working capital, contributing to a more balanced debt structure and lower financing costs.

To complete the process, Mabwell will seek shareholder approval at an extraordinary general meeting scheduled for 1 June 2026. The issuance remains contingent on both shareholder backing and NAFMII registration, and therefore may or may not proceed.

The board has requested authorization to handle all issuance-related matters, including timing, tranche size, pricing and documentation, within the approved quota and regulatory framework.

The company stated that the plan will not materially affect day-to-day operations and pledged timely disclosure of subsequent developments. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.